FORMULATION AND CHARACTERIZATION OF BLEND MICROSPHERE OF GLIMEPIRIDE
Mr. Naphis Ahamad*, Mrs. Diksha Raja Bundela, Dr. O.P. Agrawal
ABSTRACT
Glimepiride is an oral antidiabetic drug commonly prescribed for the management of type 2 diabetes mellitus. However, its short half-life and rapid elimination necessitate frequent dosing, leading to potential issues with patient compliance. To overcome these limitations and achieve sustained drug release, blend microspheres of glimepiride were formulated using mucoadhesive polymers. The mucoadhesive nature of the polymers allows prolonged drug residence time at the mucosal surfaces, enhancing drug absorption and localized drug delivery. In this study, glimepiride-loaded blend microspheres were prepared using a combination of mucoadhesive polymers through a solvent evaporation technique. The selected mucoadhesive polymers were carefully chosen based on their compatibility with glimepiride and their ability to provide sustained drug release. The prepared microspheres were characterized for their particle size, morphology, drug content, percentage yield, and entrapment efficiency. The results of the characterization indicated that the microspheres exhibited uniform particle size distribution, with a mean size suitable for mucosal adhesion. The drug content analysis confirmed the successful encapsulation of glimepiride within the microspheres. The percentage yield values indicated the efficiency of the formulation process, with formulation F3 showing the highest yield among all batches. Furthermore, the entrapment efficiency data revealed that formulation F3 also had the highest drug-loading capacity. In conclusion, the formulation and characterization of blend microspheres of glimepiride offer a promising approach for sustained drug delivery in the treatment of type 2 diabetes mellitus. The mucoadhesive nature of the polymers and the controlled drug release of the microspheres make them a potential candidate for improving the therapeutic efficacy of glimepiride and enhancing patient outcomes. Further investigations and in vivo studies are warranted to validate the optimized formulation's efficacy, safety, and pharmacological profile.
[Full Text Article]